REVOLAX™ SUB-Q

REVOLAX™ SUB-Q is provided as a sterile volume of 1.1 ml in a single-use glass syringe with two sterilized 25G mm needles. For REVOLAX™ Sub-Q, results will be effective for between 8 and 12 months.

REVOLAX™ SUB-Q is used in volumetric treatments, correction of deep wrinkles, correction of the nose, chin, cheeks, contouring.

REVOLAX™ Sub-Q has the thickest properties within the product line. With its advanced ability to mould, maintain structure, and longevity – it is recommended for the treatment of deep-sized to extremely severe wrinkles including nasolabial. This product also works best for cheek, chin, nose, and jawline augmentation that requires a thicker substance to fill.

REVOLAX™ uses high-purity non-animal hyaluronic acid, which is a 100% natural substance, optimally synchronizing with human skin tissues. The product is completely purified of the BDDE cross-linking agent, which ensures a high level of safety for the patient. REVOLAX™ is based on a unique cross-linking technology that does not require free hyaluronic acid to apply the physical properties of the gel formula. High viscoelasticity is one of the distinguishing features of REVOLAX™. This malleable consistency creates an immediate and lasting volume, and also allows the product to evenly distribute with a natural finish.

REVOLAX™ SUB-Q without Lidocaine is recommended for intradermal implantation for volume loss and morphological asymmetry of the face. It should be injected into deep subcutaneous.

Contraindications:

• Do not inject REVOLAX™ SUB-Q into the eye area (eye circle or eyelids).
• Do not inject REVOLAX™ SUB-Q into the blood vessels (intravascular).
• REVOLAX™ SUB-Q without Lidocaine should not be used in:
• Pregnant or nursing women
• Persons under 18 years of age
• Patients known to be hypersensitive to hyaluronic acid
• Patients who tend to develop hypertrophic scars
• REVOLAX™ SUB-Q should not be used in combination with laser therapy, chemical peeling, or skin abrasion.
• REVOLAX™ SUB-Q should not be used in areas with inflammatory and infectious skin problems.

After-care:

• Do not use in patients with coagulation disorders or in patients who have been treated with thrombolytic anticoagulants or platelet aggregation inhibitors within the previous 2 weeks.
• It is recommended to avoid taking aspirin, non-steroidal anti-inflammatory drugs, or high doses of vitamin C the week before the injection.
• Patients are advised not to wear makeup for 12 hours after the injection and to avoid extended exposure to sunlight, UV light, and extreme cold and heat for 2 weeks after the injection.